CO7240376A2 - Composiciones farmacéuticas y tratamiento de mastitis - Google Patents

Composiciones farmacéuticas y tratamiento de mastitis

Info

Publication number
CO7240376A2
CO7240376A2 CO14277182A CO14277182A CO7240376A2 CO 7240376 A2 CO7240376 A2 CO 7240376A2 CO 14277182 A CO14277182 A CO 14277182A CO 14277182 A CO14277182 A CO 14277182A CO 7240376 A2 CO7240376 A2 CO 7240376A2
Authority
CO
Colombia
Prior art keywords
mastitis
treatment
pharmaceutical compositions
pharmaceutical composition
relates
Prior art date
Application number
CO14277182A
Other languages
English (en)
Inventor
Robrecht Froyman
Heinz-Georg Wetzstein
Kristine Fraatz
Wolfgang Wiehl
Original Assignee
Bayer Animalhealth Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7240376(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animalhealth Gmbh filed Critical Bayer Animalhealth Gmbh
Publication of CO7240376A2 publication Critical patent/CO7240376A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica y a procedimientos de tratamiento y/o prevención de mastitis en mamíferos no humanos. Más en particular, la presente invención se refiere al tratamiento de mastitis en vacas. La composición farmacéutica comprende una mezcla de un ácido fosfónico y al menos un agente antimicrobiano.
CO14277182A 2012-06-29 2014-12-17 Composiciones farmacéuticas y tratamiento de mastitis CO7240376A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666312P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
CO7240376A2 true CO7240376A2 (es) 2015-04-17

Family

ID=48672650

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14277182A CO7240376A2 (es) 2012-06-29 2014-12-17 Composiciones farmacéuticas y tratamiento de mastitis

Country Status (22)

Country Link
US (1) US10265330B2 (es)
EP (1) EP2866812B1 (es)
JP (1) JP6246804B2 (es)
KR (1) KR20150030707A (es)
CN (2) CN104379151A (es)
AR (1) AR091603A1 (es)
AU (1) AU2013283375B2 (es)
BR (1) BR112014031866A2 (es)
CA (1) CA2877794C (es)
CL (1) CL2014003503A1 (es)
CO (1) CO7240376A2 (es)
CR (1) CR20140594A (es)
DO (1) DOP2014000300A (es)
EC (1) ECSP14033371A (es)
HK (1) HK1206623A1 (es)
IL (1) IL235768A0 (es)
MX (1) MX368153B (es)
NZ (1) NZ702087A (es)
PE (1) PE20150199A1 (es)
PH (1) PH12014502864A1 (es)
RU (1) RU2659430C2 (es)
WO (1) WO2014001353A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737047B2 (en) 2011-03-22 2017-08-22 Ccd Holdings Llc Method for the treatment, control, minimization, and prevention of bovine mastitis
US8757092B2 (en) 2011-03-22 2014-06-24 Eco-Composites Llc Animal bedding and associated method for preparing the same
PE20150199A1 (es) 2012-06-29 2015-01-31 Bayer Animal Health Gmbh Composiciones farmaceuticas y tratamiento de mastitis
EP2953624B1 (en) * 2013-02-08 2019-08-21 Luoda Pharma Limited Methods of treating microbial infections, including mastitis
EP2970586B1 (en) 2013-03-15 2022-12-07 Genzyme Corporation Amine functional polyamides
AU2014318264B2 (en) 2013-09-16 2018-10-04 Zoetis Services Llc Assembly for sequentially delivering substances, and associated methods
JP2016088918A (ja) * 2014-11-11 2016-05-23 大山乳業農業協同組合 乳房炎治療・予防用組成物、並びに、乳房炎の治療・予防方法
PL3124016T3 (pl) * 2015-07-31 2020-04-30 Warszawski Uniwersytet Medyczny Przeciwłuszczycowa kompozycja emulsyjna zawierająca cefazolinę
WO2018022451A1 (en) * 2016-07-27 2018-02-01 The Trustees Of The University Of Pennsylvania Drug target for treating veterinary infections and methods of using same
EP3998109A4 (en) * 2019-07-11 2023-07-12 Seren Pharmaceuticals Inc. NEW THERAPEUTIC AGENT AGAINST A DISEASE CAUSED BY PROTOTHECA
CA3205453A1 (en) * 2020-12-24 2022-06-30 Intervet International B.V. Methods of treating mastitis with an orthosomycin antimicrobial compound
RU2762088C1 (ru) * 2021-05-05 2021-12-15 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии" (ФГБНУ "ВНИВИПФиТ") Способ лечения мастита у коров
CN113368043A (zh) * 2021-06-11 2021-09-10 吉林大学 一种复方阿莫西林乳房注入剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034099A (en) * 1974-03-29 1977-07-05 The Upjohn Company Compositions and method for treating mastitis in milk animals
US4330529A (en) * 1978-02-15 1982-05-18 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
US4210635A (en) * 1978-02-15 1980-07-01 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
JPS62129217A (ja) * 1985-12-02 1987-06-11 Fujisawa Pharmaceut Co Ltd 医薬用殺菌組成物
KR20010022033A (ko) * 1997-07-29 2001-03-15 후루타 타케시 가축의 유선염 치료방법
MXPA06001192A (es) * 2003-07-31 2006-04-11 Pharmacia & Upjohn Co Llc Composicion farmaceutica dispersable para el tratamiento de mastitis y trastornos oticos.
DE102004054873A1 (de) * 2004-11-12 2006-05-18 Bayer Healthcare Ag Behandlung von Mastitis
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CN101744827B (zh) * 2008-12-15 2012-05-30 天津中敖生物科技有限公司 治疗鸡大肠杆菌的药物组合物及其制备方法、应用
US8449916B1 (en) * 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
EP2404601A1 (en) * 2010-07-06 2012-01-11 BioAgency AG New drug combinations for the treatment of Malaria
CN101879172B (zh) * 2010-07-13 2012-07-18 杨建彬 头孢噻呋钠复方制剂
EA021846B1 (ru) 2011-05-11 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антибактериального действия для парентерального применения, способ ее получения
PE20150199A1 (es) 2012-06-29 2015-01-31 Bayer Animal Health Gmbh Composiciones farmaceuticas y tratamiento de mastitis

Also Published As

Publication number Publication date
CN110522914A (zh) 2019-12-03
CL2014003503A1 (es) 2015-05-04
CN104379151A (zh) 2015-02-25
IL235768A0 (en) 2015-01-29
CA2877794C (en) 2020-08-04
JP2015521644A (ja) 2015-07-30
PE20150199A1 (es) 2015-01-31
CA2877794A1 (en) 2014-01-03
KR20150030707A (ko) 2015-03-20
EP2866812A1 (en) 2015-05-06
PH12014502864A1 (en) 2015-02-23
ECSP14033371A (es) 2015-09-30
AU2013283375B2 (en) 2018-04-26
US10265330B2 (en) 2019-04-23
MX368153B (es) 2019-09-20
AU2013283375A1 (en) 2014-12-18
RU2659430C2 (ru) 2018-07-02
BR112014031866A2 (pt) 2022-02-01
CR20140594A (es) 2015-02-06
HK1206623A1 (en) 2016-01-15
EP2866812B1 (en) 2017-10-04
MX2014015631A (es) 2015-04-09
RU2015102562A (ru) 2016-08-20
DOP2014000300A (es) 2015-07-15
WO2014001353A1 (en) 2014-01-03
US20150164926A1 (en) 2015-06-18
JP6246804B2 (ja) 2017-12-13
AR091603A1 (es) 2015-02-18
NZ702087A (en) 2016-12-23

Similar Documents

Publication Publication Date Title
ECSP14033371A (es) Composiciones farmacéuticas y tratamiento de mastitis
PH12016501807A1 (en) Novel compounds
MY185139A (en) Substituted imidazopyridazines
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
BR112015011430A2 (pt) composição para liberação imediata e prolongada
TN2015000371A1 (en) Substituted imidazopyridazines
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
PH12017501133A1 (en) Pyrazolopyridinamines
BR112014032759A2 (pt) composições lipídicas de racecadotril
PH12016500054A1 (en) Substituted pyrazolo-pyridinamines
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
BR112015011693A2 (pt) composições fibrinolíticas compreendendo bromelina e nattokinase para a prevenção e tratamento de estados flebotrombóticos
EP2594268A4 (en) ANGIOGENIC INHIBITORY COMPOSITION WITH MACROLACTIN A AND A DERIVATIVELY AS ACTIVE SUBSTANCES
WO2014031982A3 (en) Methods and compositions for treating pain
EA201270547A1 (ru) Фармацевтическая композиция
MX2017006747A (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
ECSP16095540A (es) Composiciones antimicrobianas con agentes efervescentes
MA39762A (fr) Nouveaux composés
TN2014000091A1 (en) Amino-substituted imidazopyridazines
PL402105A1 (pl) Kompozycja i preparat zawierające tioprolinę i kwas rozmarynowy, zastosowanie tej kompozycji oraz sposób ochrony skóry przed procesem starzenia zewnętrzpochodnego
TR201203085A2 (tr) Sefetamet ve klavulanik asit içeren bileşimler.
TR201203087A2 (tr) Seftibüten ve klavulanik asit formülasyonları.